logo
Morgan Stanley Weighs In on Tesla Stock as Musk Reallocates Resources

Morgan Stanley Weighs In on Tesla Stock as Musk Reallocates Resources

Tesla (NASDAQ:TSLA) has long considered itself much more than an EV maker, but might it have bitten off more than it can chew? Signs are pointing that way, with the company now appearing to scale back at least one of its ambitious initiatives.
Elevate Your Investing Strategy:
Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
That initiative is Dojo – Tesla's in-house supercomputer program designed to process the massive volumes of data and video collected from its vehicles to train AI models for the FSD (full self-driving) system and the Optimus robot.
Last Thursday, Bloomberg News reported that Tesla is shutting down the program, with team leader Peter Bannon set to depart, according to sources familiar with the matter. The report claims CEO Elon Musk made the call as Tesla leans more heavily on external partners like Nvidia and AMD for computing power, and Samsung Electronics for chip production. About 20 Dojo engineers have reportedly left for the startup DensityAI, while the remainder will be reassigned to other computing projects.
For Morgan Stanley analyst Adam Jonas, the news raises important strategic and financial implications. He sees the move as potentially part of a broader efficiency drive, aimed at trimming costs from a project that likely carried substantial capital and operating expenses. Tesla's Q2 results already flagged higher opex tied to AI initiatives, expanded training capacity at its Texas Gigafactory, and an FY25 capex forecast north of $9 billion – much of it earmarked for AI-related investments.
One possible beneficiary of this pivot is Musk's privately held xAI. Jonas notes that xAI has been handling a growing share of Tesla's AI 'brain' development, leveraging both social media data from X and real-world driving data from Tesla vehicles. Scaling back or eliminating Dojo could strengthen the case for tighter collaboration between the two entities.
Jonas also sees a potential shift in Tesla's focus toward robotics and edge inference capabilities. Musk has often pointed to the 'latent strategic potential' of Tesla's global vehicle fleet as a distributed inference network. With Optimus moving closer to commercialization, Jonas thinks Tesla may redirect incremental capex and R&D toward driving down robot production costs and improving manufacturability – whether for robotaxis or humanoid robots.
And timing may be on Tesla's side. The once-severe GPU shortage that Musk often cited has eased considerably, removing one of the key constraints that had made in-house compute resources like Dojo more urgent in the past.
For now, Jonas is holding firm on his Overweight (i.e., Buy) rating for TSLA stock, keeping a $410 price target that points to ~21% upside. (To watch Jonas' track record, click here)
That bullish stance stands in contrast to the broader Street, where TSLA carries 15 Holds, 14 Buys, and 8 Sells, for a Hold (i.e., Neutral) consensus overall. With shares trading at $339.03, the average price target of $307.23 points to a potential 9% pullback over the next year. (See TSLA stock forecast)
To find good ideas for stocks trading at attractive valuations, visit TipRanks' Best Stocks to Buy, a tool that unites all of TipRanks' equity insights.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...
Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...

Yahoo

time4 minutes ago

  • Yahoo

Theravance Biopharma Inc (TBPH) Q2 2025 Earnings Call Highlights: Strong Sales and Strategic ...

Release Date: August 12, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points Theravance Biopharma Inc (NASDAQ:TBPH) reported a strong quarter with net sales reaching approximately $66 million, driven by demand growth and favorable pricing. The company completed a $225 million sale of its remaining royalty interests in Trilogy to GSK, significantly strengthening its balance sheet. The phase 3 Cypress trial for amproloxetine is progressing well, with enrollment nearing completion and top-line data expected in six months. Theravance Biopharma Inc (NASDAQ:TBPH) ended the quarter with approximately $340 million in cash and no debt, maintaining a strong financial position. The company is on track to achieve significant milestones, including a potential $150 million from royalty Pharma over the next 18 months. Negative Points The company did not provide guidance on the formal launch timing for Upellry in China, as Beatrice is still finalizing the commercialization plan. There is uncertainty regarding the pricing strategy for amproloxetine, as it is still early to determine a specific price point. The company faces challenges in ensuring proper education for clinicians to make the best decisions for patient needs, particularly in specialty pharmacy channels. Theravance Biopharma Inc (NASDAQ:TBPH) expects to pay approximately $27 million in taxes related to the Trilogy royalty sale in the second half of the year. There is potential for pushback on amproloxetine pricing and reimbursement, given the presence of generics with less efficacy and clear side effects. Q & A Highlights Warning! GuruFocus has detected 7 Warning Signs with TBPH. Q: What factors contributed to the improved pull-through performance for Upellary this quarter? A: Rhonda Farnham, Chief Business Officer, explained that the improved pull-through was driven by the transition of volume to specialty pharmacy, which enhances pricing and persistency. The support patients receive in this channel improves fulfillment and persistency compared to conventional retail pharmacy. The company remains focused on providing options that best meet individual patient needs while educating clinicians to make informed decisions. Q: Can you provide an update on the outlook for Upellary's growth in China and the Cyprus trial enrollment? A: Rhonda Farnham stated that Beatrice is leading the commercialization efforts in China, and further details will be shared once their market plan is unveiled. Anya Miller, Head of Development, noted that the Cyprus trial's US versus ex-US enrollment is expected to mirror previous studies, with all data to be disclosed at the topline readout. A press release will be issued upon full enrollment of the open-label portion. Q: How is Theravance Biopharma approaching the pricing strategy for amproloxetine, and what are the considerations for reimbursement in the US? A: Rhonda Farnham mentioned that while it's early to finalize pricing, an analysis of recent rare neuro drug launches suggests an average price of approximately $380,000 per year. The company is actively engaging with payers to highlight the unmet need and the potential benefits of amproloxetine, focusing on its safety profile and durability of effect. Q: What are the expectations for SG&A expenses related to amproloxetine's commercialization, and how might they change post-data readout? A: Aziz Sala, Chief Financial Officer, indicated that SG&A expenses are expected to remain stable through the year, with some pre-launch activities already underway. Post-data readout, if positive, there will be an increase in SG&A spend, but it will be targeted and not excessively large, focusing on supporting the launch and marketing efforts. Q: Can you elaborate on the operating leverage observed in the collaboration revenue growth compared to Upellary's net sales increase? A: Aziz Sala explained that the collaboration revenue growth outpaced net sales growth due to cost reimbursements between the companies. While this quarter showed a significant gap, future quarters may not see the same level of disparity. However, profit margins are expected to continue improving as net sales grow. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus.

Elon Musk Suffers Legal Blow in War With Sam Altman
Elon Musk Suffers Legal Blow in War With Sam Altman

Newsweek

time6 minutes ago

  • Newsweek

Elon Musk Suffers Legal Blow in War With Sam Altman

Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Newsweek AI is in beta. Translations may contain inaccuracies—please refer to the original content. Elon Musk will have to face court charges of running a "years-long harassment campaign" against OpenAI after a judge refused his request to dismiss the case. US District Judge Yvonne Gonzalez Rogers ruled on Tuesday that Musk would face allegations of weaponized legal claims and continued social media attacks against his former business colleague-turned-rival Sam Altman, and the artificial intelligence company that they co-founded together, which produces ChatGPT. Musk asked for the counterclaim, which was filed in April, to be dismissed, as the latest stage in a legal battle between Musk and Altman over the management of OpenAI, which Musk departed from in 2019. This is a developing story and will be updated.

Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)
Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)

Business Insider

time18 minutes ago

  • Business Insider

Bank of America Securities Sticks to Its Buy Rating for Apple (AAPL)

Bank of America Securities analyst Wamsi Mohan maintained a Buy rating on Apple yesterday and set a price target of $250.00. The company's shares closed yesterday at $229.65. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. According to TipRanks, Mohan is a 5-star analyst with an average return of 13.2% and a 61.64% success rate. Mohan covers the Technology sector, focusing on stocks such as Apple, Seagate Tech, and International Business Machines. In addition to Bank of America Securities, Apple also received a Buy from Goldman Sachs's Mike Ng in a report issued on August 8. However, on August 7, DZ BANK AG maintained a Hold rating on Apple (NASDAQ: AAPL). The company has a one-year high of $260.10 and a one-year low of $169.21. Currently, Apple has an average volume of 56.07M. Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of AAPL in relation to earlier this year. Most recently, in May 2025, Chris Kondo, the CAO of AAPL sold 4,486.00 shares for a total of $933,940.34.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store